cell growth processes

Summary

Summary: Processes required for CELL ENLARGEMENT and CELL PROLIFERATION.

Top Publications

  1. ncbi CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles
    Dagmar Beier
    Laboratory of Neurooncology, University of Regensburg, Regensburg, Germany
    Cancer Res 67:4010-5. 2007
  2. ncbi A novel function for galectin-7: promoting tumorigenesis by up-regulating MMP-9 gene expression
    Mélanie Demers
    INRS Institut Armand Frappier, University of Quebec, Laval, Quebec, Canada
    Cancer Res 65:5205-10. 2005
  3. ncbi Gene expression profiling revealed survivin as a target of 3,3'-diindolylmethane-induced cell growth inhibition and apoptosis in breast cancer cells
    Km Wahidur Rahman
    Department of Pathology, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan 48201, USA
    Cancer Res 66:4952-60. 2006
  4. ncbi Caveolin-1 mediates tumor cell migration and invasion and its regulation by miR-133a in head and neck squamous cell carcinoma
    Nijiro Nohata
    Department of Functional Genomics, Graduate School of Medicine, Chiba University, Chiba, Japan
    Int J Oncol 38:209-17. 2011
  5. ncbi Oncostatin M induces growth arrest by inhibition of Skp2, Cks1, and cyclin A expression and induced p21 expression
    Hartmut Halfter
    Department of Neurology, Westfalische Wilhelms Universitat Munster, Munster, Germany
    Cancer Res 66:6530-9. 2006
  6. ncbi Antitumor effects of EMAP II against pancreatic cancer through inhibition of fibronectin-dependent proliferation
    Roderich E Schwarz
    UT Southwestern Medical Center, Department of Surgery, Division of Surgical Oncology, Dallas, TX, USA
    Cancer Biol Ther 9:632-9. 2010
  7. ncbi Targeting the Wnt signaling pathway with dishevelled and cisplatin synergistically suppresses mesothelioma cell growth
    Kazutsugu Uematsu
    Division of Clinical Oncology, Tokai University School of Medicine, Isehara, Kanagawa 259 1193, Japan
    Anticancer Res 27:4239-42. 2007
  8. ncbi miR-21 induces cell cycle at S phase and modulates cell proliferation by down-regulating hMSH2 in lung cancer
    Zhiwei Zhong
    Institute of Biochemistry and Molecular Biology, School of Medicine, Ningbo University, 818 Fenghua Road, Ningbo 315211, China
    J Cancer Res Clin Oncol 138:1781-8. 2012
  9. pmc MicroRNA miR-98 inhibits tumor angiogenesis and invasion by targeting activin receptor-like kinase-4 and matrix metalloproteinase-11
    Vinayakumar Siragam
    Sunnybrook Health Sciences Centre, University of Toronto, Canada
    Oncotarget 3:1370-85. 2012
  10. pmc Ras inhibition boosts galectin-7 at the expense of galectin-1 to sensitize cells to apoptosis
    Batya Barkan
    Department of Neurobiology, The George S Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel
    Oncotarget 4:256-68. 2013

Research Grants

Detail Information

Publications255 found, 100 shown here

  1. ncbi CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles
    Dagmar Beier
    Laboratory of Neurooncology, University of Regensburg, Regensburg, Germany
    Cancer Res 67:4010-5. 2007
    ..The remainder stems from previously unknown CD133(-) tumor cells with apparent stem cell-like properties but distinct molecular profiles and growth characteristics in vitro and in vivo...
  2. ncbi A novel function for galectin-7: promoting tumorigenesis by up-regulating MMP-9 gene expression
    Mélanie Demers
    INRS Institut Armand Frappier, University of Quebec, Laval, Quebec, Canada
    Cancer Res 65:5205-10. 2005
    ..Our results have uncovered the existence of a previously undescribed activity, the promotion of cancer cell malignancy, to galectin-7...
  3. ncbi Gene expression profiling revealed survivin as a target of 3,3'-diindolylmethane-induced cell growth inhibition and apoptosis in breast cancer cells
    Km Wahidur Rahman
    Department of Pathology, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan 48201, USA
    Cancer Res 66:4952-60. 2006
    ..These results suggest that targeting survivin by 3,3'-diindolylmethane could be a new and novel approach for the prevention and/or treatment of breast cancer...
  4. ncbi Caveolin-1 mediates tumor cell migration and invasion and its regulation by miR-133a in head and neck squamous cell carcinoma
    Nijiro Nohata
    Department of Functional Genomics, Graduate School of Medicine, Chiba University, Chiba, Japan
    Int J Oncol 38:209-17. 2011
    ..Therefore, CAV1 functions as an oncogene in HNSCC. The identification of tumor suppressive miRNAs and their target genes could provide new insights into potential mechanism of HNSCC carcinogenesis...
  5. ncbi Oncostatin M induces growth arrest by inhibition of Skp2, Cks1, and cyclin A expression and induced p21 expression
    Hartmut Halfter
    Department of Neurology, Westfalische Wilhelms Universitat Munster, Munster, Germany
    Cancer Res 66:6530-9. 2006
    ..The accumulation of two CDK inhibitor proteins and the repression of cyclin A expression may explain the broad and potent antiproliferative effect of the cytokine...
  6. ncbi Antitumor effects of EMAP II against pancreatic cancer through inhibition of fibronectin-dependent proliferation
    Roderich E Schwarz
    UT Southwestern Medical Center, Department of Surgery, Division of Surgical Oncology, Dallas, TX, USA
    Cancer Biol Ther 9:632-9. 2010
    ..These findings suggest that EMAP II demonstrates significant antitumor activity against PDAC cells, and that this effect may be in part mediated through targeted interference with stromal FN-integrin dependent PDAC cell proliferation...
  7. ncbi Targeting the Wnt signaling pathway with dishevelled and cisplatin synergistically suppresses mesothelioma cell growth
    Kazutsugu Uematsu
    Division of Clinical Oncology, Tokai University School of Medicine, Isehara, Kanagawa 259 1193, Japan
    Anticancer Res 27:4239-42. 2007
    ....
  8. ncbi miR-21 induces cell cycle at S phase and modulates cell proliferation by down-regulating hMSH2 in lung cancer
    Zhiwei Zhong
    Institute of Biochemistry and Molecular Biology, School of Medicine, Ningbo University, 818 Fenghua Road, Ningbo 315211, China
    J Cancer Res Clin Oncol 138:1781-8. 2012
    ..The aim of this study is to investigate the role of miR-21 in hMSH2 gene expression and the effect of miR-21 on cell proliferation and cell cycle in lung cancer...
  9. pmc MicroRNA miR-98 inhibits tumor angiogenesis and invasion by targeting activin receptor-like kinase-4 and matrix metalloproteinase-11
    Vinayakumar Siragam
    Sunnybrook Health Sciences Centre, University of Toronto, Canada
    Oncotarget 3:1370-85. 2012
    ..Our findings define a regulatory role of miR-98 in tumor angiogenesis and invasion through repressed ALK4 and MMP11 expression...
  10. pmc Ras inhibition boosts galectin-7 at the expense of galectin-1 to sensitize cells to apoptosis
    Batya Barkan
    Department of Neurobiology, The George S Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel
    Oncotarget 4:256-68. 2013
    ..These findings suggest that FTS, alone or in combination with chemotherapy agents, may be worth developing as a possible treatment for MPNSTs...
  11. ncbi Rapid heterogeneous liver-cell on-chip patterning via the enhanced field-induced dielectrophoresis trap
    Chen Ta Ho
    Department of Power Mechanical Engineering, National Tsing Hua University, Hsinchu, Taiwan 300, ROC
    Lab Chip 6:724-34. 2006
    ..This work reports the rapid in-parallel patterning of the dual types of live liver cells via the enhanced DEP trap inside the microfluidic chip...
  12. ncbi Anti-prostate stem cell antigen monoclonal antibody 1G8 induces cell death in vitro and inhibits tumor growth in vivo via a Fc-independent mechanism
    Zhennan Gu
    Department of Urology and Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA 90095 1738, USA
    Cancer Res 65:9495-500. 2005
    ..These results suggest that the anti-PSCA mAb 1G8 acts by a direct, Fc-independent mechanism to inhibit prostate tumor growth both in vitro and in vivo...
  13. ncbi The Rho kinase inhibitor fasudil inhibits tumor progression in human and rat tumor models
    Han Ying
    RBA Oncology, Berlex Biosciences, Richmond, CA 94803, USA
    Mol Cancer Ther 5:2158-64. 2006
    ..In patients, fasudil is well tolerated without any serious adverse reactions. Therefore, the concept of Rho kinase inhibition as an antimetastatic therapy for cancer can now be clinically explored...
  14. pmc Growth-rate regulated genes have profound impact on interpretation of transcriptome profiling in Saccharomyces cerevisiae
    Birgitte Regenberg
    Institut für Molekulare Biowissenschaften, Johann Wolfgang Goethe Universitat, Max von Laue Str, 9, 60438 Frankfurt am Main, Germany
    Genome Biol 7:R107. 2006
    ..We used continuous cultures to control growth rate and studied the transcriptional program of the model eukaryote Saccharomyces cerevisiae, with generation times varying between 2 and 35 hours...
  15. ncbi Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells
    Steven J Isakoff
    Department of Cell Biology, Harvard Medical School, Boston, Massachusetts 02115, USA
    Cancer Res 65:10992-1000. 2005
    ..Together, these data support the notion that the cancer-associated mutations in PIK3CA may significantly contribute to breast cancer pathogenesis and represent attractive targets for therapeutic inhibition...
  16. pmc Expression of a protease-resistant insulin-like growth factor-binding protein-4 inhibits tumour growth in a murine model of breast cancer
    A J Ryan
    Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, 123 St Stephens Green, Dublin 2, Ireland
    Br J Cancer 101:278-86. 2009
    ..Bioavailability of IGF1 is modulated by IGF-binding proteins (IGFBPs). IGFBP4 inhibits IGF1 activity but cleavage by pregnancy-associated plasma protein-A (PAPP-A) protease releases active IGF1...
  17. pmc Ferritin overexpression for noninvasive magnetic resonance imaging-based tracking of stem cells transplanted into the heart
    Anna V Naumova
    Department of Radiology, University of Washington, Seattle, WA 98109, USA
    Mol Imaging 9:201-10. 2010
    ..These experiments lay the groundwork for using the MRI gene reporter ferritin to track stem cells transplanted to the heart...
  18. pmc Galectin-7 is epigenetically-regulated tumor suppressor in gastric cancer
    Seok Jun Kim
    Department of Biochemistry and Molecular Biology, Yonsei University College of Medicine, 50 Yonsei ro, Seodaemun gu, Seoul, Republic of Korea
    Oncotarget 4:1461-71. 2013
    ..Further study of galectin-7 regulation may lead to improved gastric cancer diagnosis and therapy. ..
  19. ncbi Differential expression and function of caveolin-1 in human gastric cancer progression
    Elke Burgermeister
    Department of Medicine II, Klinikum rechts der Isar, Technical University of München, Munich, Germany
    Cancer Res 67:8519-26. 2007
    ..These data indicate that caveolin-1 exhibits a stage-dependent differential expression and function in GC and may thereby contribute to its pathogenesis...
  20. ncbi Association of double-positive FOXA1 and FOXP1 immunoreactivities with favorable prognosis of tamoxifen-treated breast cancer patients
    Nobuhiro Ijichi
    Division of Gene Regulation and Signal Transduction, Research Center for Genomic Medicine, Saitama Medical University, Saitama, Japan
    Horm Cancer 3:147-59. 2012
    ....
  21. ncbi PRL-3 promotes the proliferation of LoVo cells via the upregulation of KCNN4 channels
    Wei Lai
    Department of Gastroenteropancreatic Surgery, Medical Research Center, Sun Yat Sen Memorial Hospital, Sun Yat Sen University, Guangzhou 510120, PR China
    Oncol Rep 26:909-17. 2011
    ..In conclusion, PRL-3 promoted the proliferation of LoVo cells through upregulation of KCNN4 channels which facilitated the G2/M transition...
  22. ncbi In vitro modeling of human pancreatic duct epithelial cell transformation defines gene expression changes induced by K-ras oncogenic activation in pancreatic carcinogenesis
    Jiaying Qian
    Ontario Cancer Institute Princess Margaret Hospital, University Health Network, Toronto, Ontario, Canada
    Cancer Res 65:5045-53. 2005
    ..The in vitro modeling of human pancreatic duct epithelial cell transformation may provide mechanistic insights on gene expression changes that occur during multistage pancreatic duct cell carcinogenesis...
  23. pmc Inhibition of nuclear factor kappa-B signaling reduces growth in medulloblastoma in vivo
    Susan E Spiller
    Department of Pediatrics, University of Alabama at Birmingham, 35294, USA
    BMC Cancer 11:136. 2011
    ..Nuclear factor kappa-B (NFκB) is a signaling pathway that controls transcriptional activation of genes important for tight regulation of many cellular processes and is aberrantly expressed in many types of cancer...
  24. pmc Cyr61 mediates hepatocyte growth factor-dependent tumor cell growth, migration, and Akt activation
    C Rory Goodwin
    Kennedy Krieger Institute, Johns Hopkins School of Medicine, Baltimore, MD, USA
    Cancer Res 70:2932-41. 2010
    ..05). These results identify a Cyr61-dependent pathway by which c-Met activation mediates cell growth, cell migration, and long-lasting signaling events in glioma cell lines and possibly astroglial malignancies...
  25. ncbi Synergistic effect of cyclin D1 and c-Myc leads to more aggressive and invasive mammary tumors in severe combined immunodeficient mice
    Yong Wang
    Department of Pathology, Barbara Ann Karmanos Cancer Institute, Hudson Webber Cancer Research Center, Wayne State University School of Medicine, Detroit, MI, USA
    Cancer Res 67:3698-707. 2007
    ..In summary, overexpression of cyclin D1 may commit mammary epithelia to a tumor-prone phenotype in which cooperation with other genes, such as synergy with c-myc, may lead to a more aggressive phenotype...
  26. ncbi Tumor suppressive microRNA-375 regulates lactate dehydrogenase B in maxillary sinus squamous cell carcinoma
    Takashi Kinoshita
    Department of Functional Genomics, Chiba University Graduate School of Medicine, 1 8 1 Inohana Chuo ku, Chiba 260 8670, Japan
    Int J Oncol 40:185-93. 2012
    ..The identification of a cancer network regulated by the miR-375 tumor suppressor could provide new insights into the molecular mechanisms of MSSCC oncogenesis...
  27. ncbi Plumbagin induces G2-M arrest and autophagy by inhibiting the AKT/mammalian target of rapamycin pathway in breast cancer cells
    Po Lin Kuo
    Cell Biology Laboratory, Department of Biotechnology, Chia Nan University of Pharmacy and Science, Tainan 717, Taiwan
    Mol Cancer Ther 5:3209-21. 2006
    ..Taken together, these results imply a critical role for AKT inhibition in plumbagin-induced G2-M arrest and autophagy of human breast cancer cells...
  28. pmc Caveolin-1 upregulation mediates suppression of primary breast tumor growth and brain metastases by stat3 inhibition
    Wen Tai Chiu
    Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Res 71:4932-43. 2011
    ..Collectively, our findings provide clinical and mechanistic evidence that Cav-1 is a critical target for suppression by Stat3 in driving invasion and metastasis of breast cancer cells...
  29. ncbi Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma
    Riccardo Taulli
    Center for Experimental Research and Medical Studies CERMS, University of Turin, Turin, Italy
    Cancer Res 66:4742-9. 2006
    ....
  30. ncbi MEK1/2 inhibitors AS703026 and AZD6244 may be potential therapies for KRAS mutated colorectal cancer that is resistant to EGFR monoclonal antibody therapy
    Juyong Yoon
    Translational Research Center for Protein Function Control and Department of Biotechnology, College of Life Science and Biotechnology, Yonsei University, Seodaemun gu, Seoul, Korea
    Cancer Res 71:445-53. 2011
    ..Our findings offer proof-of-concept for the use of MEK inhibitors as an effective therapy in K-ras mutated CRC...
  31. ncbi ZD6474, a dual tyrosine kinase inhibitor of EGFR and VEGFR-2, inhibits MAPK/ERK and AKT/PI3-K and induces apoptosis in breast cancer cells
    Siddik Sarkar
    School of Medical Science and Technology, Indian Institute of Technology Kharagpur, Kharagpur, West Bengal, India
    Cancer Biol Ther 9:592-603. 2010
    ..Collectively, these data imply that ZD6474 a dual kinase inhibitor has potential for the targeted therapy of breast cancer...
  32. ncbi Increased EP4 receptor expression in colorectal cancer progression promotes cell growth and anchorage independence
    Simon D Chell
    Cancer Research UK Colorectal Tumour Biology Research Group, Department of Cellular and Molecular Medicine, Faculty of Medical and Veterinary Science, Bristol University, UK
    Cancer Res 66:3106-13. 2006
    ..We propose that high levels of PGE(2) in a tumor microenvironment would select for cells with increased EP4 expression, and that the EP4 receptor may therefore represent an important target for colorectal cancer prevention and treatment...
  33. ncbi Pharmacologic inhibition of RAF-->MEK-->ERK signaling elicits pancreatic cancer cell cycle arrest through induced expression of p27Kip1
    Stephan Gysin
    Cancer Research Institute and Department of Cellular and Molecular Pharmacology, University of California, San Francisco Comprehensive Cancer Center, San Francisco, California 94115, USA
    Cancer Res 65:4870-80. 2005
    ..Moreover, these data suggest that pharmacologic inhibition of the RAF-->MEK-->ERK signaling pathway alone might tend to have a cytostatic, as opposed to a cytotoxic, effect on pancreatic cancer cells...
  34. ncbi Resveratrol suppresses growth of human ovarian cancer cells in culture and in a murine xenograft model: eukaryotic elongation factor 1A2 as a potential target
    Mee Hyun Lee
    Department of Pharmacy, College of Pharmacy, and Cancer Research Institute, Seoul National University, Seoul, South Korea
    Cancer Res 69:7449-58. 2009
    ..Taken together, eEF1A2 may be considered as a potential molecular target for the antiproliferative effects of resveratrol in PA-1 ovarian cancer cells...
  35. ncbi Lack of correlation between p53-dependent transcriptional activity and the ability to induce apoptosis among 179 mutant p53s
    Yuichi Kakudo
    Department of Clinical Oncology, Institute of Development, Aging and Cancer, and Tohoku University Hospital, Tohoku University, Sendai, Japan
    Cancer Res 65:2108-14. 2005
    ..These results suggested that transactivation-dependent apoptosis does not always play a major role in p53-dependent apoptosis, indirectly supporting the importance role of the transactivation-independent mechanism...
  36. ncbi A selective phosphatase of regenerating liver phosphatase inhibitor suppresses tumor cell anchorage-independent growth by a novel mechanism involving p130Cas cleavage
    Sherif Daouti
    Preclinical Research, Hoffmann La Roche, Inc, Nutley, New Jersey 07110, USA
    Cancer Res 68:1162-9. 2008
    ..This study reveals a new insight into the role of PRL-3 in priming tumor progression and shows that PRL may represent an attractive target for therapeutic intervention in cancer...
  37. ncbi Activation of the nuclear factor kappaB pathway by astrocyte elevated gene-1: implications for tumor progression and metastasis
    Luni Emdad
    Department of Pathology, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, College of Physicians and Surgeons, 630 West 168th Street, New York, NY 10032, USA
    Cancer Res 66:1509-16. 2006
    ..Our findings suggest that activation of NF-kappaB by AEG-1 could represent a key molecular mechanism by which AEG-1 promotes anchorage-independent growth and invasion, two central features of the neoplastic phenotype...
  38. ncbi Survivin as a radioresistance factor, and prognostic and therapeutic target for radiotherapy in rectal cancer
    Franz Rodel
    Department of Radiation Oncology, Institutes of Clinical Immunology, and Pathology, University of Erlangen Nuremberg, Erlangen, Germany
    Cancer Res 65:4881-7. 2005
    ....
  39. ncbi Identification of tumorsphere- and tumor-initiating cells in HER2/Neu-induced mammary tumors
    Jeff C Liu
    Division of Cell and Molecular Biology, Toronto General Research Institute University Health Network, Toronto, Ontario, Canada
    Cancer Res 67:8671-81. 2007
    ..In addition, the similarity between TICs and TFUs in this system provides a rationale for TFU-based screens to target tumor-initiating cells in HER2(+) breast cancer...
  40. ncbi Human malignant melanomas express receptors for luteinizing hormone releasing hormone allowing targeted therapy with cytotoxic luteinizing hormone releasing hormone analogue
    Gunhild Keller
    Endocrine, Polypeptide and Cancer Institute, Veterans Affairs Medical Center, New Orleans, Louisiana 70112 1262, USA
    Cancer Res 65:5857-63. 2005
    ..LHRH receptors are expressed in a very high percentage of human malignant melanoma specimens and can be used for targeted chemotherapy with cytotoxic LHRH analogue AN-207...
  41. pmc Immunotherapeutic suppression of indoleamine 2,3-dioxygenase and tumor growth with ethyl pyruvate
    Alexander J Muller
    Lankenau Institute for Medical Research, Wynnewood, Pennsylvania 19096, USA
    Cancer Res 70:1845-53. 2010
    ..Further, these findings rationalize oncologic applications for this agent by providing a compelling basis to reposition ethyl pyruvate as a low-cost immunochemotherapy for clinical evaluation in cancer patients...
  42. ncbi Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors
    Xing Fan
    Department of Pathology, Johns Hopkins University School of Medicine, 720 Rutland Avenue, Baltimore, MD 21205, USA
    Cancer Res 66:7445-52. 2006
    ..Stem-like cells in brain tumors thus seem to be selectively vulnerable to agents inhibiting the Notch pathway...
  43. pmc Transplanting normal vascular proangiogenic cells to tumor-bearing mice triggers vascular remodeling and reduces hypoxia in tumors
    Junpei Sasajima
    Division of Gastroenterology and Hematology Oncology, Department of Medicine, Asahikawa Medical College, Asahikawa, Hokkaido, Japan
    Cancer Res 70:6283-92. 2010
    ..Together, our findings identify a novel alternate approach to regulate abnormal tumor vessels, offering the potential to improve the delivery and efficacy of anticancer drugs to hypoxic tumors...
  44. pmc Toll-like receptor 9 agonist IMO cooperates with everolimus in renal cell carcinoma by interfering with tumour growth and angiogenesis
    V Damiano
    Dipartimento di Endocrinologia ed Oncologia Molecolare e Clinica, Universita di Napoli Federico II, Naples, Italy
    Br J Cancer 108:1616-23. 2013
    ....
  45. ncbi Vascular endothelial growth factor receptor 3 is involved in tumor angiogenesis and growth
    Pirjo Laakkonen
    Molecular Cancer Biology Research Program and Ludwig Institute for Cancer Research, Biomedicum Helsinki, Haartman Institute and Helsinki University Central Hospital, University of Helsinki, Finland
    Cancer Res 67:593-9. 2007
    ..These results suggest that the VEGFR-3 pathway contributes to tumor angiogenesis and that effective inhibition of tumor progression may require the inhibition of multiple angiogenic targets...
  46. ncbi MicroRNA let-7a down-regulates MYC and reverts MYC-induced growth in Burkitt lymphoma cells
    Valerie B Sampson
    Department of Molecular Genetics, Cellular and Tissue Transplantation, Alfred I duPont Hospital for Children, Wilmington, Delaware 19803, and Center for Applied Genomics, Public Health Research Institute, UMDNJ New Jersey Medical School, Newark, USA
    Cancer Res 67:9762-70. 2007
    ....
  47. ncbi RNA interference targeting aurora kinase a suppresses tumor growth and enhances the taxane chemosensitivity in human pancreatic cancer cells
    Tatsuo Hata
    Department of Molecular Pathology, Tohoku University School of Medicine, Sendai Miyagi, Japan
    Cancer Res 65:2899-905. 2005
    ..These results indicate that inhibition of AURKA expression can result in potent antitumor activity and chemosensitizing activity to taxanes in human pancreatic cancer...
  48. ncbi A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo
    Houda Jallal
    Department of Medicine and Oncology, McGill University Health Center, 687 Pine Avenue West, Montreal, Quebec, Canada
    Cancer Res 67:1580-8. 2007
    ..Together, the results from these studies provide compelling evidence for the role of Src inhibitors as therapeutic agents for blocking breast cancer growth and metastasis...
  49. ncbi Identification of OTX2 as a medulloblastoma oncogene whose product can be targeted by all-trans retinoic acid
    Chunhui Di
    Brain Tumor Center, Department of Pathology, Duke University Medical Center, Research Drive, Durham, NC 27710, USA
    Cancer Res 65:919-24. 2005
    ..These observations suggest that OTX2 is essential for the pathogenesis of anaplastic medulloblastomas and that these tumors may be amenable to therapy with all-trans-retinoic acid...
  50. ncbi A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6
    Linda B Baughn
    Department of Pathology, Weill Medical College of Cornell University, 1300 York Avenue, New York, NY 10021, USA
    Cancer Res 66:7661-7. 2006
    ..PD 0332991, therefore, represents the first promising and specific inhibitor for therapeutic targeting of Cdk4/6 in multiple myeloma and possibly other B-cell cancers...
  51. ncbi Akt1 ablation inhibits, whereas Akt2 ablation accelerates, the development of mammary adenocarcinomas in mouse mammary tumor virus (MMTV)-ErbB2/neu and MMTV-polyoma middle T transgenic mice
    Ioanna G Maroulakou
    Molecular Oncology Research Institute and Department of Pathology, Tufts New England Medical Center, 750 Washington Street, Boston, MA 02111, USA
    Cancer Res 67:167-77. 2007
    ....
  52. ncbi A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients
    Hongyue Dai
    Rosetta Inpharmatics LLC, A wholly owned subsidiary of Merck and Co Inc Seattle, Washington, USA
    Cancer Res 65:4059-66. 2005
    ..Our work presented here may contribute a crucial step towards rational design of personalized treatment...
  53. ncbi Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies
    Marcus M Schittenhelm
    Department of Medicine, Division of Hematology Oncology, Oregon Health and Science University, Portland, USA
    Cancer Res 66:473-81. 2006
    ..Our studies suggest that dasatinib may have clinical efficacy against human neoplasms that are associated with gain-of-function KIT mutations...
  54. ncbi Activated tyrosine kinase Ack1 promotes prostate tumorigenesis: role of Ack1 in polyubiquitination of tumor suppressor Wwox
    Nupam P Mahajan
    Lineberger Comprehensive Cancer Center, Department of Medicine and Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599 7295, USA
    Cancer Res 65:10514-23. 2005
    ..Further, these findings suggest that Ack1 could be a novel therapeutic target for prostate cancer...
  55. ncbi Functional genomics identifies TOR-regulated genes that control growth and division
    David A Guertin
    Whitehead Institute for Biomedical Research and Massachusetts Institute of Technology, Nine Cambridge Center, Cambridge, Massachusetts 02142, USA
    Curr Biol 16:958-70. 2006
    ..Recent efforts have identified at least two multiprotein complexes that contain TOR, but little is known in higher eukaryotes about the genes downstream of TOR that control growth...
  56. ncbi Doxorubicin-DNA adducts induce a non-topoisomerase II-mediated form of cell death
    Lonnie P Swift
    Department of Biochemistry, La Trobe University, Victoria, Australia
    Cancer Res 66:4863-71. 2006
    ....
  57. ncbi The expression of CD30 in anaplastic large cell lymphoma is regulated by nucleophosmin-anaplastic lymphoma kinase-mediated JunB level in a cell type-specific manner
    Faye Yuan yi Hsu
    Department of Biochemistry, Norris Cancer Center, University of Southern California Keck School of Medicine, Los Angeles, California 90033, USA
    Cancer Res 66:9002-8. 2006
    ..Combination of NPM-ALK repression and CD30 ligand leads to significantly increased tumor cell growth inhibition compared with one method alone, suggesting its potential application for ALCL-specific cancer treatment...
  58. ncbi Functional gene expression analysis uncovers phenotypic switch in aggressive uveal melanomas
    Michael D Onken
    Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St Louis, Missouri 63110, USA
    Cancer Res 66:4602-9. 2006
    ..These findings reveal new roles for Id2 and E-cadherin in uveal melanoma progression, and they identify potential targets for therapeutic intervention...
  59. pmc MiR-15a and MiR-16 control Bmi-1 expression in ovarian cancer
    Resham Bhattacharya
    Department of Biochemistry, College of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer Res 69:9090-5. 2009
    ..These findings suggest the development of therapeutic strategies by restoring miR-15a and miR-16 expression in ovarian cancer and in other cancers that involve upregulation of Bmi-1...
  60. ncbi Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts
    Licun Wu
    Department of Medical Oncology and Hematology and Division of Experimental Therapeutics, Princess Margaret Hospital and University of Toronto, Toronto, Ontario, Canada
    Cancer Res 65:2825-31. 2005
    ..Our results suggest that repopulation of PTEN-negative cancer cells between courses of chemotherapy might be inhibited by CCI-779...
  61. ncbi Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors
    Teresa Burgess
    Department of Oncology Research, Amgen, Inc, One Amgen Center Drive, Thousand Oaks, CA 91320 1799, USA
    Cancer Res 66:1721-9. 2006
    ..These results suggest that an antibody to an epitope in the beta-chain of HGF has potential as a novel therapeutic agent for treating patients with HGF-dependent tumors...
  62. ncbi Curcumin induces apoptosis in human neuroblastoma cells via inhibition of NFkappaB
    Christian Freudlsperger
    Institut für Anatomie II Experimentelle Morphologie, Universitätsklinikum Hamburg Eppendorf 20246 Hamburg, Germany
    Anticancer Res 28:209-14. 2008
    ....
  63. ncbi Nitrogen-containing bisphosphonate, YM529/ONO-5920, inhibits macrophage inflammatory protein 1 alpha expression and secretion in mouse myeloma cells
    Masanobu Tsubaki
    Division of Pharmacotherapy, Kinki University School of Pharmacy, Kowakae, Higashi Osaka 577 8502, Japan
    Cancer Sci 99:152-8. 2008
    ..Accordingly, YM529/ONO-5920 appears to have promise for use in effective future therapy for osteolysis and myeloma cell growth that depends on MIP-1 alpha...
  64. pmc Identification and characterization of GRIM-1, a cell-death-associated gene product
    EDWARD R HOFMANN
    Greenebaum Cancer Center, Department of Microbiology and Immunology, Molecular and Cellular Cancer Biology Track, GPILS, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    J Cell Sci 123:2781-91. 2010
    ..Together, these studies identified a novel protein involved in growth suppression and cell death...
  65. ncbi The role of constitutively active signal transducer and activator of transcription 3 in ovarian tumorigenesis and prognosis
    Daniel G Rosen
    Department of Pathology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 107:2730-40. 2006
    ....
  66. ncbi 7,12-dimethylbenz(a)anthracene treatment of a c-rel mouse mammary tumor cell line induces epithelial to mesenchymal transition via activation of nuclear factor-kappaB
    Sangmin Ryan Shin
    Department of Biochemistry and Environmental Health, Boston University Medical Campus, Massachusetts 02118, USA
    Cancer Res 66:2570-5. 2006
    ..The aberrant c-Rel expression present in most human breast cancers suggests that this mechanism may play an important role in carcinogenesis...
  67. ncbi Proenzyme therapy of cancer
    Josef F Novak
    Bucknell University, Department of Biology, Lewisburg, Pennsylvania 17837, USA
    Anticancer Res 25:1157-77. 2005
    ..In conclusion, we have discovered that proenzyme therapy, mandated first by John Beard nearly one hundred years ago, shows remarkable selective effects that result in growth inhibition of tumor cells with metastatic potential...
  68. ncbi Overexpression of a secretory leukocyte protease inhibitor in human gastric cancer
    Wan Li Cheng
    Department of Biochemistry, Chang Gung University, Taoyuan, Taiwan, Republic of China
    Int J Cancer 123:1787-96. 2008
    ..4-fold to 6.9-fold, or 3.0-fold to 4.1-fold, respectively, in SLPI-overexpressing cell lines. The results point to SLPI as a potential prognostic marker for gastric cancer and its function in cell invasion...
  69. ncbi Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib
    Alan Serrels
    The Beatson Institute for Cancer Research, Garscube Estate, Switchback Road, Glasgow, G61 1BD, United Kingdom
    Mol Cancer Ther 5:3014-22. 2006
    ..Thus, peripheral blood mononuclear cells may provide a useful surrogate tissue for biomarker studies with dasatinib using inhibition of Src Tyr(419) and paxillin Tyr(118) phosphorylation as read-outs of Src activity...
  70. pmc The neuroendocrine-derived peptide parathyroid hormone-related protein promotes prostate cancer cell growth by stabilizing the androgen receptor
    John DaSilva
    Department of Microbiology and Cancer Center, University of Virginia Health System, Charlottesville, Virginia 22908 0734, USA
    Cancer Res 69:7402-11. 2009
    ..These events result in increased accumulation of AR and thus enhanced growth of prostate cancer cells at low levels of androgen...
  71. ncbi Fluvastatin and cisplatin demonstrate synergistic cytotoxicity in epithelial ovarian cancer cells
    Barbie Taylor-Harding
    Women s Cancer Research Institute and Division of Gynecologic Oncology, Burns and Allen Research Institute, Cedars Sinai Medical Center, Los Angeles, CA, USA
    Gynecol Oncol 119:549-56. 2010
    ..We hypothesized that statins have a cytotoxic effect and that the combination of fluvastatin and cisplatin inhibits cellular proliferation in epithelial ovarian cancer cells...
  72. pmc Dynamics of haemopoiesis across mammals
    David Dingli
    Division of Hematology, College of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Proc Biol Sci 275:2389-92. 2008
    ..This unified view, which is compatible with the existing data, suggests that there was no need for major adaptations in the architecture of haemopoiesis across mammals...
  73. ncbi Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo
    Lori Jerome
    Department of Oncology, McGill University, West, Montreal, Quebec, Canada
    Cancer Res 66:7245-52. 2006
    ..These results emphasize the merit of evaluating simultaneous blockade of the HER-2 and IGF-IR pathways using combination therapy with rhIGFBP-3 plus Herceptin in human clinical trials of patients with HER-2-positive breast cancer...
  74. ncbi Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus
    Donatella Del Bufalo
    Laboratory of Experimental Chemotherapy and Division of Medical Oncology A, Regina Elena National Cancer Institute, Rome, Italy
    Cancer Res 66:5549-54. 2006
    ..Overall, these results suggest that antiangiogenic effects may substantially contribute to the antitumor activity observed with temsirolimus in breast cancer...
  75. pmc Aberrant activation of androgen receptor in a new neuropeptide-autocrine model of androgen-insensitive prostate cancer
    Joy C Yang
    Department of Urology and Biological Chemistry, School of Medicine, University of California at Davis, Sacramento, CA 95817, USA
    Cancer Res 69:151-60. 2009
    ..This xenograft model shows autocrine, neuropeptide- and Src kinase-mediated progression of androgen-independent CaP postcastration, and is potentially useful for testing novel therapeutic agents...
  76. ncbi Use of a chemically modified antisense oligonucleotide library to identify and validate Eg5 (kinesin-like 1) as a target for antineoplastic drug development
    Erich Koller
    Department of Functional Genomics, Isis Pharmaceuticals, Carlsbad, California 92008, USA
    Cancer Res 66:2059-66. 2006
    ..These data show, for the first time, the utility of a 2'MOE ASO library for high-throughput cell culture-based functional assays and suggest that an Eg5 ASO also has potential in a therapeutic strategy...
  77. pmc Diffusion-limited tumour growth: simulations and analysis
    Philip Gerlee
    Center for Models of Life, Niels Bohr Institute, Blegdamsvej 17, 2200 Copenhagen O, Denmark
    Math Biosci Eng 7:385-400. 2010
    ..Comparison between the prediction of the stability analysis and the results from the simulations shows good agreement between theory and simulation...
  78. ncbi Loss of the hSNF5 gene concomitantly inactivates p21CIP/WAF1 and p16INK4a activity associated with replicative senescence in A204 rhabdoid tumor cells
    Jingjing Chai
    Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, North Carolina 27599 7295, USA
    Cancer Res 65:10192-8. 2005
    ..In summary, our studies suggest that hSNF5 loss may influence the regulation of multiple CDK inhibitors involved in replicative senescence...
  79. pmc Identification of a novel synthetic thiazolidin compound capable of inducing c-Jun NH2-terminal kinase-dependent apoptosis in human colon cancer cells
    Fuminori Teraishi
    Department of Thoracic and Cardiovascular Surgery, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 65:6380-7. 2005
    ..DBPT and its analogues might be useful as anticancer agents...
  80. ncbi CaSm-mediated cellular transformation is associated with altered gene expression and messenger RNA stability
    Melissa M Fraser
    Department of Pathology and Laboratory Medicine, Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina 29403, USA
    Cancer Res 65:6228-36. 2005
    ....
  81. ncbi Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells
    Aldo Maria Roccaro
    Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02115, USA
    Cancer Res 66:184-91. 2006
    ..These data, therefore, delineate the mechanisms of the antiangiogenic effects of bortezomib on multiple myeloma cells in the bone marrow milieu...
  82. ncbi Growth promoting signaling by tenascin-C [corrected]
    Christian Ruiz
    Friedrich Miescher Institute for Biomedical Research, Novartis Forschungsstiftung, Basel, Switzerland
    Cancer Res 64:7377-85. 2004
    ....
  83. ncbi Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2- cancer cells are similarly tumorigenic
    Lubna Patrawala
    Department of Carcinogenesis, Science Park Research Division, The University of Texas M D Anderson Cancer Center, Smithville, Texas 78957, USA
    Cancer Res 65:6207-19. 2005
    ....
  84. ncbi Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties
    Dario Ponti
    Department of Experimental Oncology and Laboratories, Istituto Nazionale Tumori, Milan, Italy
    Cancer Res 65:5506-11. 2005
    ....
  85. ncbi Specific growth rate versus doubling time for quantitative characterization of tumor growth rate
    Esmaeil Mehrara
    Departments of Radiation Physics and Surgery, Goteborg University, Goteborg, Sweden
    Cancer Res 67:3970-5. 2007
    ..SGR is also more accurate to use when discussing, for example, growth fraction, cell loss rate, and growth rate heterogeneities within the tumor. SGR should thus be used, instead of DT, to quantify tumor growth rate...
  86. pmc Tumor growth rates derived from data for patients in a clinical trial correlate strongly with patient survival: a novel strategy for evaluation of clinical trial data
    Wilfred D Stein
    Medical Oncology Branch, National Cancer Institute, Center for Cancer Research, National Institutes of Health, Bethesda, Maryland 20892, USA
    Oncologist 13:1046-54. 2008
    ..The slow progress in developing new cancer therapies can be attributed in part to the long time spent in clinical development. To hasten development, new paradigms especially applicable to patients with metastatic disease are needed...
  87. ncbi Most C6 cells are cancer stem cells: evidence from clonal and population analyses
    Xuesheng Zheng
    Second Affiliated Hospital, School of Medicine, Zhejiang University corrected Hangzhou corrected China
    Cancer Res 67:3691-7. 2007
    ..Thus, we concluded that the C6 line was mainly composed of cancer stem cells, although many of them were neither CD133+ nor side population...
  88. ncbi Prostate stem cell antigen vaccination induces a long-term protective immune response against prostate cancer in the absence of autoimmunity
    Maria de la Luz Garcia-Hernandez
    Department of Molecular Microbiology and Immunology and Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California 90033, USA
    Cancer Res 68:861-9. 2008
    ..The possibility of inducing long-term protection against prostate cancer by vaccination at the earliest signs of its development has the potential to cause a dramatic paradigm shift in the treatment of this disease...
  89. ncbi Protein kinase D1-mediated phosphorylation and subcellular localization of beta-catenin
    Cheng Du
    Department of Surgery, Division of Urology, University of Massachusetts Medical School, Worcester, Massachusett 01655, USA
    Cancer Res 69:1117-24. 2009
    ..Understanding the molecular basis of PKD1-beta-catenin interaction provides a novel strategy to target beta-catenin function in cells including prostate cancer...
  90. ncbi Iron chelators deferoxamine and diethylenetriamine pentaacetic acid induce apoptosis in ovarian carcinoma
    Laurent Brard
    Program in Women s Oncology, Department of Obstetrics and Gynecology, Women and Infants Hospital, Brown University, Providence, RI 02905, USA
    Gynecol Oncol 100:116-27. 2006
    ..We have evaluated the anti-proliferative activities of iron chelators, deferoxamine (DFO), and diethylenetriamine pentaacetic acid (DTPA), in human and rat ovarian cancer cells...
  91. ncbi Characterization of CSOC 882, a novel immortalized ovarian cancer cell line expressing EGFR, HER2, and activated AKT
    Daniel R Scoles
    Women s Cancer Research Institute at Samuel Oschin Comprehensive Cancer Institute and Division of Gynecologic Oncology, CSMC Burns and Allen Research Institute, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Gynecol Oncol 104:120-8. 2007
    ..We describe a new ovarian cancer cell line that arose from primary culture of a stage IC, grade III ovarian carcinoma, designated CSOC 882...
  92. ncbi Target genes suitable for silencing approaches and protein product interference in ovarian epithelial cancer
    Anastasia Malek
    Institute of Pathology, Charite Universitatsmedizin Berlin, Germany
    Cancer Treat Rev 36:8-15. 2010
    ....
  93. ncbi Combining the farnesyltransferase inhibitor lonafarnib with paclitaxel results in enhanced growth inhibitory effects on human ovarian cancer models in vitro and in vivo
    Stacey A Taylor
    Schering Plough Research Institute, Biological Research Oncology, 2015 Galloping Hill Road, K15 2 2700, Kenilworth, NJ 07033, USA
    Gynecol Oncol 109:97-106. 2008
    ....
  94. ncbi Antitumor activity of 4-(N-hydroxyphenyl)retinamide conjugated with poly(L-glutamic acid) against ovarian cancer xenografts
    Changping Zou
    Department of Ob Gyn, Division of Gynecologic Oncology, University of Connecticut, Carole and Ray Neag Comprehensive Cancer Center, USA
    Gynecol Oncol 107:441-9. 2007
    ..The purpose of this study was to develop and evaluate a water-soluble polymeric formulation of 4HPR that can release 4HPR over a period of a few days...
  95. ncbi Triptolide induces pancreatic cancer cell death via inhibition of heat shock protein 70
    Phoebe A Phillips
    Department of Surgery, University of Minnesota, Minneapolis, Minnesota 55488, USA
    Cancer Res 67:9407-16. 2007
    ..Triptolide is a potential therapeutic agent that can be used to prevent the progression and metastases of pancreatic cancer...
  96. ncbi A comparison of two orally bioavailable anti-cancer agents, IRC-110160 and STX140
    Paul A Foster
    Endocrinology and Metabolic Medicine and Sterix Ltd, Faculty of Medicine, Imperial College London, St Mary s Hospital, London W2 1NY, UK
    Anticancer Res 28:1483-91. 2008
    ..This study characterises two recently developed anticancer agents in vitro and in vivo, 2-methoxyoestra-1,3,5(10), 16-tetraene-3-carboxamide (IRC-110160) and STX140...
  97. ncbi Oral cancer overexpressed 1 (ORAOV1): a regulator for the cell growth and tumor angiogenesis in oral squamous cell carcinoma
    Lu Jiang
    State Key Laboratory of Oral Diseases, West China College of Stomatology, Sichuan University, Chengdu, China
    Int J Cancer 123:1779-86. 2008
    ..Taken together, we demonstrate that ORAOV1 plays pivotal roles in the growth and angiogenesis of OSCC. Thus, ORAOV1 may be a novel target that could be explored to develop therapeutic strategy in OSCC management...
  98. ncbi A potent indole-3-carbinol derived antitumor agent with pleiotropic effects on multiple signaling pathways in prostate cancer cells
    Jing Ru Weng
    Department of Biological Science and Technology, China Medical University, Taiwan
    Cancer Res 67:7815-24. 2007
    ..In conclusion, the ability of OSU-A9 to target multiple aspects of cancer cell survival with high potency suggests its clinical value in prostate cancer therapy...
  99. pmc Functional characterization of filamin a interacting protein 1-like, a novel candidate for antivascular cancer therapy
    Mijung Kwon
    Tumor Angiogenesis Section, Surgery Branch, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Cancer Res 68:7332-41. 2008
    ..Overall, these findings suggest that the novel protein FILIP1L may be an important mediator of the effects of angiogenesis inhibitors and that FILIP1L has the potential to be an antivascular reagent for cancer therapy...
  100. ncbi Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with fluoropyrimidine anticancer agent, S-1, on tumor growth of human oral squamous cell carcinoma xenografts in nude mice
    Yasutaka Itashiki
    Department of Therapeutic Regulation for Oral Tumors, Institute of Health Bioscience, University of Tokushima Graduate School, Tokushima, Japan
    Anticancer Res 27:2365-75. 2007
    ..S-1 is a new oral antineoplastic agent that can induce apoptosis in various types of cancer cells, including OSCC. Hence, combined treatment of cancer cells with TRAIL and S-1 might exert dramatic antitumor effects on OSCC cells...
  101. pmc Over-expression of adenine nucleotide translocase 1 (ANT1) induces apoptosis and tumor regression in vivo
    Ji Young Jang
    Department of Pathology, Tumor Immunity Medical Research Center, Cancer Research Institute, Seoul National University College of Medicine, 28 Yeongeon dong, Jongno gu, Seoul 110 799, South Korea
    BMC Cancer 8:160. 2008
    ..In particular, over-expression of ANT1 induces apoptosis in cultured tumor cells...

Research Grants75

  1. Cell growth control by cell and organelle size-dependent ribosome biogenesis
    Clifford P Brangwynne; Fiscal Year: 2012
    ..the biophysical mechanism by which the nucleolus may provide cell size feedback for regulating cell growth, which will have important implications for understanding and controlling physiological and disease driven cell growth processes.
  2. INTERACTIONS OF THE A1 AND A2 PROTEINS OF S CEREVISIAE
    Susan Baxter; Fiscal Year: 1999
    ..identified in eukaryotes from yeast to human and play critical roles in development differentiation and cell growth processes. In particular, the a1 protein is related closely to the pbx1 homeodomain of the chimeric fusion protein ..
  3. INTERACTIONS OF THE A1 AND A2 PROTEINS OF S CEREVISIAE
    GRISELDA HERNANDEZ; Fiscal Year: 2001
    ..identified in eukaryotes from yeast to human and play critical roles in development differentiation and cell growth processes. In particular, the a1 protein is related closely to the pbx1 homeodomain of the chimeric fusion protein ..
  4. ROLE OF POLYAMINES IN CALMODULIN AND C-KINASE REGULATION
    John Walters; Fiscal Year: 1990
    ..enzymes during this interval, this could partially account for their significant influence on cell growth processes. We will examine the role of polyamines in terms of their interaction with CaM and C-K, and determine the ..
  5. Glycosaminoglycan-based inhibitors for treatment of prostate cancer
    Vinata B Lokeshwar; Fiscal Year: 2010
    ..If proven efficacious, sHA compounds and 4-MU will be a novel class of glycosaminoglycan-based target-specific anti-tumor drugs. ..
  6. Glycosaminoglycans For IC Pathophysiology and Prognosis
    Vinata Lokeshwar; Fiscal Year: 2005
    ..Furthermore, it might yield a test or a combination of tests that can be used in the follow-up of IC patients and for monitoring 9 treatment responses. ..
  7. Colon Cancer and Mitochondria
    Barbara Heerdt; Fiscal Year: 2006
    ..abstract_text> ..
  8. Short chain fatty acid metabolism and colonic tumorigenesis
    Barbara Heerdt; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  9. Enzyme therapy for hyperhomocysteinemia
    Yuying Tan; Fiscal Year: 2005
    ..Phase II results will lead to an IND for MEGC-PEG-rMETase for end stage renal disease patients and other patients with intractable hyperhomocysteinemia and high cardiovascular disease mortality. ..
  10. Imageable tumor-targeting bacteria
    Ming Zhao; Fiscal Year: 2006
    ..unreadable] [unreadable] [unreadable]..
  11. Targeted tumoricidal bacteria
    Ming Zhao; Fiscal Year: 2007
    ..Future human trials of the tumor-killing bacteria can be held after the Phase I and Phase II grant periods are completed. [unreadable] [unreadable] [unreadable]..
  12. Dual-color tumor-host imaging models
    Meng Yang; Fiscal Year: 2007
    ..These models have significant commercial potential for discovery and development of stroma-targeted and anti-angiogenesis drugs. [unreadable] [unreadable] [unreadable]..
  13. The Role of Tuberin in Smooth Muscle Cell Proliferation
    Geraldine Finlay; Fiscal Year: 2007
    ..abstract_text> ..
  14. Therapeutic hair follicle-derived neurospheres
    Meng Yang; Fiscal Year: 2007
    ..Human hair- follicle bulge cells will be further characterized and developed for therapeutic potential for nerve regeneration in Phase III. [unreadable]..
  15. Orthotopic models of tumor angiogenesis and blood flow
    Meng Yang; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  16. Adenoviral GFP targeting of metastatic human tumors using multiple delivery route
    Hiroyuki Kishimoto; Fiscal Year: 2008
    ..Having obtained these results, we can move forward in the Phase II grant application with experiments to bring OBP-401 to the clinic for use in cancer surgery in human patients. [unreadable] [unreadable] [unreadable]..
  17. Clostridial genome-scale metabolic and regulatory model of differentiation
    RYAN SENGER; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  18. Discovery of novel fluorescent reporter genes
    Ming Zhao; Fiscal Year: 2004
    ..Reporters with spectral properties that can be used for whole-body imaging of tumors in the lung and their metastases will be candidates for further development for numerous applications of multi-color imaging. ..
  19. MITOCHONDRIA AND APOPTOSIS OF MAMMARY EPITHELIAL CELLS
    Barbara Heerdt; Fiscal Year: 2001
    ..abstract_text> ..
  20. Inhibitors of 5alpha-reductase for acne therapy
    Lingna Li; Fiscal Year: 2002
    ..PROPOSED COMMERCIAL APPLICATIONS: Liposomal 4-MA will be developed as a topical selectively targeted therapeutic for acne for which they should be a very market. ..
  21. RHOMOCYCSTEINASE FOR HOMOCYSTEINE ASSAY
    Yuying Tan; Fiscal Year: 2002
    ..The tHCY enzymatic kits for these applications will be ready for commercial launch at this point. PROPOSED COMMERCIAL APPLICATION: Not Available ..
  22. Long-Circulating Liposomal Camptothecins CAP and EAP
    Roman Perez Soler; Fiscal Year: 2003
    ..Ultimately, we will seek formulation(s) that display optimized drug retention and in vivo and in vitro performance. PROPOSED COMMERCIAL APPLICATION: Not Available ..
  23. Progestogen Inhibition of Ovarian Cancer Cell Metastasis
    William Murdoch; Fiscal Year: 2003
    ....
  24. COX-2 Inhibitor and N-3PUFA in Colon Cancer Prevention
    Nanjoo Suh; Fiscal Year: 2007
    ..Clear delineation of the synergistic effects in preclinical models will allow the rational design of human clinical trials. ..
  25. HEPATITIS C VIRUS NS5A PROTEIN AND PATHOGENESIS
    Ratna Ray; Fiscal Year: 2003
    ..Results from this study will lead to a better understanding of the virus mediated pathogenesis. The long term goal of this study is to design effective strategies for the intervention of HCV mediated disease in humans. ..
  26. MOLECULAR TOXICOLOGY IN HUMAN KIDNEY CELLS
    Lawrence Lash; Fiscal Year: 2007
    ..Achievement of these aims should build on our previous work in human kidney cells and extend it to provide a much more complete understanding of the various and complex ways in which DCVC affects the human kidney [unreadable] [unreadable]..
  27. Growth Factors and Colon Cancer
    MARTHA OR MARTY SLATTERY; Fiscal Year: 2006
    ..This study builds on a unique existing resource to study genetic and environmental associations with colorectal cancer. It will provide insight into colon cancer etiology and therefore avenues to disease prevention. ..
  28. GLUTATHIONE AND MITOCHONDRIA IN TOXIC RENAL INJURY
    Lawrence Lash; Fiscal Year: 2003
    ..This information may have therapeutic applications for prevention of renal cellular injury or for understanding mitochondrial diseases or age-related decreases that occur in mitochondrial function. ..
  29. Determinants of Resistance to Erlotinib in NSCLC
    Roman Perez Soler; Fiscal Year: 2010
    ..To confirm the predictive value of the algorithm in a group of patients with chemoresistant NSCLC selected for their high probability of achieving a response or stable disease with single agent erlotinib therapy. ..
  30. GENE SPECIFIC MUTATIONS IN SKIN INDUCED BY PEROXYNITRITE
    Fredika Robertson; Fiscal Year: 2001
    ..The hypothesis driving this research is that NO and peroxynitrite are mutagenic, and could be important contributors to oxidative DNA damage and mutation in human epidermal keratinocytes at sites of inflammation. ..
  31. AUTOMATED DNA ANALYSIS SYSTEM
    TERRI KINZY; Fiscal Year: 2001
    ..Trained personnel of the core facility will run and maintain all equipment to ensure optimal quality and speed. These personnel will also provide ongoing technical support to all users of this equipment. ..
  32. TUMOR OXYGENATION, VASCULARIZATION, AND RADIORESPONSE
    Bruce Fenton; Fiscal Year: 2009
    ..These results with lead to the more rational and optimal design of effective combined therapies, thereby ultimately accelerating their implementation into clinical protocols. ..
  33. AMPHIPATHIC ORAL CHELATORS AND RADIONUCLIDE CONTAMINATION
    Scott Miller; Fiscal Year: 2008
    ..Because the pharmacology and toxicology of PACA chelators, such as DTPA and EDTA, are quite well understood, the development pathway of the related TT- based chelators may proceed rapidly. ..
  34. FASEB Summer Research Conference 2008 - Melatonin Receptors: Actions and Therapeu
    David Blask; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable] [unreadable]..
  35. Akt Inhibitors to Treat Ewing's Sarcoma
    Jeffrey Toretsky; Fiscal Year: 2005
    ..Our findings from this Phase I Sun will hopefully lead to a key compound that can be further developed in a Phase II STTR ultimately leading to clinical trials in patients with ESFT. ..
  36. PREVENTION OF COLORECTAL CANCER BY iNOS AND COX-2 SELECTIVE INHIBITORS
    CHINTHALAPALLY RAO; Fiscal Year: 2008
    ..abstract_text> ..
  37. Discovery of Novel Cytotoxic Agents for Advanced Melanoma
    Wei Li; Fiscal Year: 2008
    ..This is a high risk, innovative proposal to discover a non-surgical means for a more selective and curative pharmacologic therapy for advanced melanoma. [unreadable] [unreadable] [unreadable]..
  38. Radiosensitization with the HIV protease inhibior Nelfinavir in NSCLC
    Anjali Gupta; Fiscal Year: 2008
    ..Specific Aim 3. To investigate in vitro the molecular mechanisms by which NFV results in sensitization. [unreadable] [unreadable] [unreadable]..
  39. Regulation of the P13K/AKT pathway in Waldenstrom Macroglobulinemia
    Irene Ghobrial; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  40. SQUAMOUS EPITHELIAL CELL INVASION IN ORGAN CULTURE
    James Varani; Fiscal Year: 2001
    ..abstract_text> ..
  41. Biacore T100
    Jeffrey Toretsky; Fiscal Year: 2006
    ..These enhanced capabilities of the T100 will allow projects investigating many types of biologic processes to advance. ..
  42. Role of CRH in skin physiology and pathology
    Andrzej Slominski; Fiscal Year: 2004
    ..g., melanocytes and keratinocytes, and test the role of CRH/CRH-R1 axis in the regulation of human hair growth. ..
  43. CATIONIC LIPID/P53 GENE THERAPY IN LUNG CANCER PATIENTS
    Roman Perez Soler; Fiscal Year: 2003
    ..The results of this study will provide initial but very valuable information on the potential use of this new strategy in the treatment of bronchial premalignancy, carcinoma in situ, and endobronchial lung tumors. ..
  44. MECHANISMS OF SKELETAL RECONSTITUTION AFTER LACTATION
    Scott Miller; Fiscal Year: 2004
    ..abstract_text> ..
  45. Silibinin in Prostate Cancer Chemoprevention & Treatment
    Michael Pollak; Fiscal Year: 2004
    ..The work is justified by the favorable toxicity profile of silibinin, together with prior positive laboratory studies reported by our group and other investigators. ..
  46. Gene Therapy, Neural Grafts & Parkinson's Disease
    DAVID YUREK; Fiscal Year: 2005
    ..These studies will also determine if combinations of viral vectors expressing different neurotrophic factors can be used to improve the therapeutic effects of dopamine grafts. ..
  47. Typhoon 9410 Variable Mode Imager
    John Kyriakis; Fiscal Year: 2005
    ..abstract_text> ..
  48. TRAINING PROGRAM IN CLINICAL RESEARCH
    David Schteingart; Fiscal Year: 2004
    ..abstract_text> ..
  49. A Highly Versatile Insertional Mutagenesis System
    Bruce Lahn; Fiscal Year: 2003
    ..These will include a large genetrap library, and a standard collection of transgenic mice useful for systematic interrogation of diverse trapped genes. ..
  50. Structure of Eukaryotic Translation Elongation Factor 1
    TERRI KINZY; Fiscal Year: 2004
    ..With S. cerevisiae, the structural information obtained on eEF1A can be utilized for molecular genetic analysis of the critical residues for function and regulation. ..
  51. INNOVATIVE TUMOR TARGETED THERAPIES FOR LUNG CANCER
    Roman Perez Soler; Fiscal Year: 2004
    ..Four such candidates have already been identified. It is anticipated that a total of ten young clinical investigators will be mentored during a five-year period. ..
  52. MENTORED ORIENTED RESEARCH CAREER DEVELOPMENT AWARD
    Jared Gollob; Fiscal Year: 2004
    ....
  53. P53 AND MOUSE MAMMARY TUMORIGENESIS
    Daniel Medina; Fiscal Year: 2004
    ..In summary, this model allows one to analyze the biological, genetic and molecular consequences of p53 gene deletion in the in situ mammary gland by taking advantage of transplantation methods. ..
  54. Molecular Mechanisms of MIG-10 function in axon guidance
    Christopher Quinn; Fiscal Year: 2005
    ..Information from this project will be beneficial in understanding disorders of the nervous system as well as the molecular basis of cancer. ..
  55. Molecular Modulators of Breast-Bone Metastasis
    John Price; Fiscal Year: 2004
    ..This proposal represents a unique opportunity to identify novel modulators of breast-bone metastasis. ..
  56. Chemoprevention of murine urinary bladder carcinogenesis
    Ashish Kamat; Fiscal Year: 2005
    ..abstract_text> ..
  57. Signaling Pathways that Determine Ewings Sarcoma Outcome
    Jeffrey Toretsky; Fiscal Year: 2008
    ..Clearly, if PTPL1 is validated as a supportive oncoprotein and the pathways modulated by PTPL1 are identified, patients with many other tumors that rely on IGF-IR signaling including breast carcinoma could benefit from our findings. ..
  58. PHYTOMELATONIN AND CANCER PREVENTION
    David Blask; Fiscal Year: 2004
    ....
  59. LIGHT DURING DARKNESS AND BREAST CANCER PROGRESSION
    David Blask; Fiscal Year: 2004
    ....
  60. Molecular Signaling in Decidualization
    SANJOY KUMAR DAS; Fiscal Year: 2010
    ..abstract_text> ..
  61. Obesity, Inflammation and Response to Therapy in Asthma
    EVERETT RAND SUTHERLAND; Fiscal Year: 2010
    ..End of Abstract) ..
  62. Functional Genomics Tools for HER2 heterodimers and Androgen Receptor Signaling
    Anjali Jain; Fiscal Year: 2007
    ..Androgen receptor is one such protein. Our research proposes to develop methods to search for compounds that specifically block the androgen receptor in prostate cancer cells. [unreadable]..
  63. HCV NS5A protein and pathogenesis
    Ratna Ray; Fiscal Year: 2005
    ..This study may also lead to discovery of new therapeutic modalities against persistent HCV infection that affects over 170 million people worldwide. ..
  64. Control of Vascular Smooth Muscle Function by Insulin
    Louis Ragolia; Fiscal Year: 2006
    ..abstract_text> ..
  65. ASPECTS OF UTERINE CELL CYCLE REGULATION IN IMPLANTATION
    Sanjoy Das; Fiscal Year: 2005
    ..Since these processes are analogous to pseudomalignancy, the results should also provide basic information relevant to cancer biology. ..
  66. Exposure to beef growth promoter in breast cancer
    YOUNG LIN; Fiscal Year: 2003
    ....
  67. Carolina Cardiopulmonary Gene Expression Services
    WINSTON PATTERSON; Fiscal Year: 2005
    ..abstract_text> ..
  68. "Ligand Independent" endocrine disruption by pesticides
    Patrick Wong; Fiscal Year: 2005
    ..abstract_text> ..
  69. Clofarabine: Cytarabine Activation for Leukemia Response
    Stefan Faderl; Fiscal Year: 2004
    ..abstract_text> ..
  70. FUNCTIONAL ROLE OF MBP 1
    Ratna Ray; Fiscal Year: 2006
    ..To investigate the mechanism by which it induces apoptosis To test the biological effect of MBP-1 disruption in KO mice To determine whether adenovirus-mediated MBP-1 gene transfer can regress tumor growth in vivo. ..
  71. Myocyte signaling and the response to stress
    WINSTON PATTERSON; Fiscal Year: 2009
    ....
  72. Targeted Liposomal Doxorubicin Delivery to Leukemia
    Robert Lee; Fiscal Year: 2007
    ..abstract_text> ..
  73. Aging, Stress and Atherosclerosis
    WINSTON PATTERSON; Fiscal Year: 2003
    ..Based on these studies, we will create molecular portraits of the ROS-dependent and ROS-independent transcripts preferentially associated with aging. ..